https://www.selleckchem.com/pr....oducts/dihydroethidi
have been expected from clinical trial data. Altogether, these data encourage the use of T-VEC in this special patient cohort. To assess the long-term outcome of performing uterine artery embolization (UAE) using small particles in women with symptomatic adenomyosis (AD). Twenty-seven consecutive women (median age 42 years, range 29-53 years) with AD, in eight cases AD combined with fibroids, who underwent UAE between February 2015 and January 2019, were retrospectively analyzed. The embolization was performed using small-sized
Like
Comment
Share
